Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe.
Deleuran M, Dézfoulian B, Elberling J, Knutar I, Lapeere H, Lossius AH, Schuttelaar MLA, Stockman A, Wikström E, Bradley M, de Bruin-Weller M, Gutermuth J, Mandelin JM, Schmidt MC, Thyssen JP, Vestergaard C. Deleuran M, et al. Among authors: schuttelaar mla. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):31-41. doi: 10.1111/jdv.19512. Epub 2023 Oct 11. J Eur Acad Dermatol Venereol. 2024. PMID: 37818828 Review.
[Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN, Oosterhaven JAF, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA. Voorberg AN, et al. Among authors: schuttelaar mla. Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227. Ned Tijdschr Geneeskd. 2019. PMID: 30945835 Dutch.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Deleuran M, et al. Among authors: schuttelaar mla. J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30. J Am Acad Dermatol. 2020. PMID: 31374300 Free article. Clinical Trial.
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: schuttelaar mla. Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31. Allergy. 2020. PMID: 31593343
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: schuttelaar mla. J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16. J Am Acad Dermatol. 2021. PMID: 32946967
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
Oosterhaven JAF, Spekhorst LS, Zhang J, Voorberg AN, Romeijn GLE, Boesjes CM, de Graaf M, de Bruin-Weller MS, Schuttelaar MLA. Oosterhaven JAF, et al. Among authors: schuttelaar mla. J Dermatolog Treat. 2022 Jun;33(4):1986-1989. doi: 10.1080/09546634.2021.1937485. Epub 2021 Jun 21. J Dermatolog Treat. 2022. PMID: 34151695
176 results